Background: Metabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.
Aim: To evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.
J Cardiovasc Med (Hagerstown)
November 2013
Aims: The laboratory diagnosis of diabetes mellitus is traditionally established by measurements of fasting blood glucose, random blood glucose with associated symptoms, and through the oral glucose tolerance test. A single measurement of glycated hemoglobin (A1C) eliminates practical difficulties of the above-mentioned methods. The optimal cut-off values of A1C for the screening of diabetic patients in the context of acute coronary syndrome are being investigated.
View Article and Find Full Text PDF